The results of this study indicate that, compared with palbociclib and fulvestrant monotherapy, the addition of inavolisib significantly prolonged PFS and OS in patients with PIK3CA-mutated, HR+/HER2− advanced breast cancer. Here, ERBB2 is linked to breast cancer.